or Try an Advanced Search...

    Fungal Infections Stocks List

    Symbol Grade Name % Change
    SCYX F SCYNEXIS, Inc. 6.12
    GILD F Gilead Sciences, Inc. 0.23
    View As Page of Charts
    Related Industries: Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Fungal Infection Medicine Angina Anti Infectives Antibiotics Biopharmaceutical Cardiovascular Disease Coronavirus Cyclophilin Cystic Fibrosis Cytomegalovirus Retinitis Disease Dog Drugs Dry Eye Disease Eye Eye Diseases Gilead Sciences HIV Hepatitis C

    Related ETFs - A few ETFs which own one or more of the above listed Fungal Infections stocks.

    Symbol Grade Name Weight
    IBB D iShares Nasdaq Biotechnology Index Fund 8.16
    IBBQ D Invesco Nasdaq Biotechnology ETF 8.12
    BBH D Market Vectors Biotech ETF 7.99
    BIS A ProShares UltraShort Nasdaq Biotechnology 7.41
    BIB D ProShares Ultra Nasdaq Biotechnology 6.01
    View all Fungal Infections ETFs...
    Compare ETFs
    Compare IBB to BIB Compare IBBQ to BIB Compare IBBQ to BIS

        Fungal Infections Stocks Recent News

        Date Stock Title
        Apr 26 GILD Q1 2024 Gilead Sciences Inc Earnings Call
        Apr 26 GILD FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
        Apr 26 GILD Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
        Apr 26 GILD Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
        Apr 26 GILD Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript
        Apr 26 GILD Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation
        Apr 25 GILD Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus
        Apr 25 GILD Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
        Apr 25 GILD Gilead Beats Earnings Expectations After Rocky Quarter
        Apr 25 GILD Gilead Sciences Inc (GILD) Q1 2024 Earnings: Misses Analyst EPS Estimates Amid Significant ...
        Apr 25 GILD Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
        Apr 25 GILD Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again
        Apr 25 GILD Gilead Sciences in charts: Revenue from oncology rises most among products; Veklury dips in Q1
        Apr 25 GILD Gilead posts quarterly loss on acquisition charge, revenue rises 5%
        Apr 25 GILD Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M
        Apr 25 GILD Gilead Sciences Announces First Quarter 2024 Financial Results
        Apr 25 GILD US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
        Apr 24 GILD Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus
        Apr 24 GILD What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
        Apr 23 GILD Incyte (INCY) Earnings Expected to Grow: Should You Buy?
        Related Industries: Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Fungal Infection Medicine Angina Anti Infectives Antibiotics Biopharmaceutical Cardiovascular Disease Coronavirus Cyclophilin Cystic Fibrosis Cytomegalovirus Retinitis Disease Dog Drugs Dry Eye Disease Eye Eye Diseases Gilead Sciences HIV Hepatitis C
        Fungal Infections

        Fungal infections are caused by microscopic fungi that can live on the skin, nails, and hair. They can cause a variety of symptoms, including itching, redness, and scaling. Fungal infections can be treated with antifungal medications.

        Browse All Tags